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Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Although a wide range of therapeutic options is
available, the efficacy of these methods and the prognosis of patients with HCC remain very poor. This study was conducted to
evaluate the efficacy and safety of viscum fraxini-2 in patients with chemotherapy–naı ¨ve, advanced hepatocellular carcinoma. 23
patients with unrespectable HCC who had received no prior systemic chemotherapy with objectively measurable tumors were
enrolled on this study. The mistletoe preparation for the study is an aqueous injectable solution. It contains one milliliter of viscum
fraxini in dilution stage–2 (15mg extract of 20mg mistletoe herb from ash tree, diluted in di-natrium-mono-hydrogen phosphate,
ascorbic acid and water) which is equivalent to 10000ng/ml injection ampoules. 2 ampoules of viscum fraxini–2 were administered
subcutaneously once weekly. As assessed by conventional imaging criteria, 3 (13.1%) patients have achieved complete response, 2
(8.1%) patients have achieved a partial response. 9 (39.1%) had progressive disease while 9 (39.1%) patients didn’t have evaluation of
response due to early death. The median overall survival time for all patients was 5 months (range 2–38 months), for those who
achieved a CR was 29 months (range 12–38 months) and, for those who achieved a PR was 6.5 months (range 6–7 months). The
median progression free survival for all patients was 2 months (range 1–38 months), for those who achieved a CR, it was 29 months
(range 8–38 months) and for those who achieved a partial response, it was 5 months (range 4–6 months). No hematologic toxicity
has been encountered. The spectrum of non-hematologic toxicity was mild. The WHO toxicity criteria grade 3–4 were 34.8% drug
related fever, 13.1% erthyma at injection site and 17.4% pain at the site of injection. No drug related discontinuation or toxic deaths
have occurred. Viscum fraxini-2 seems to be particularly promising in patients with advanced HCC, it shows antitumor activity and
low toxicity profile. Further studies in combination with other active agents are clearly warranted.
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Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide. Although it is far less common in western
countries, it is the most common malignant tumor in areas of
Africa and Asia (Bosch and Munoz, 1991; Lotze et al, 1993).
Although a wide range of therapeutic options is available, the
efficacy of these methods and the prognosis of patients with HCC
remain very poor. Surgical resection represents the only possibility
of cure. However, resection rates for patients with HCC remain low
because of a high incidence of associated cirrhosis, the direct
invasion of the tumor into the portal or the hepatic veins, or early
spread to the entire liver. Many non-surgical local treatments, such
as cryosurgery and radiation therapy, have been proposed;
however, considerable uncertainty remains about their effective-
ness (Venook, 1994). Eventually, in most patients with HCC, the
disease progress to a far-advanced stage for which effective local
treatment is not available. These findings stress the pressing need
for efficacious, systemic chemotherapy for patients with inoper-
able HCC.
The role of chemotherapy in the treatment of patients with HCC
remains controversial. Numerous single chemotherapeutic agents
and drug combinations have been given to HCC patients in an
attempt to alter their predictably short survival time. Unfortu-
nately, the activity of a single agent is limited, with only a few
drugs showing a response rate 410%. Moreover, combination
chemotherapy has proven equally disappointing, because addi-
tional drugs have resulted in increased toxicity without any
increased efficacy compared with single–agent doxorubicin
therapy (Whang-Peng and Chao, 1998). Therefore, there is no
drug or protocol of treatment that can be recommended as
standard therapy for this group of patients. Due to the lack of any
effective systemic chemotherapy, there is an urgent need to
investigate new drugs.
Viscum album L. is a semi parasitic plant growing on different
host trees (Becker, 1986). The extracted mistletoes are composed of
many biologically active substances. The principle of the mistletoe
phytotherapeutics can be considered as combined cytotoxic and
biological response modifying activities that result from the
activities of the plant lectins and other biologically relevant
substances (Zarkovic et al, 2001). In 1920, Steiner recommended
the mistletoe as a remedy against cancer (Steiner, 1961). In a
systematic review on controlled clinical trials, twenty-three studies
were identified: 16 randomized, 2 quasi-randomized and 5
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lnon-randomized. Cancer sites included breast, lung, stomach,
colon, rectum, head and neck, kidney, bladder, melanoma, glioma,
and genital. Among these studies, statistically significant positive
outcomes were reported for survival (n¼8), tumor remission
(n¼1), overall quality of life (n¼3), and quality of life in relation
to side effects during cytoreductive therapy (n¼3) (Kienle et al,
2003).
Viscum Fraxini is an aqueous extract of mistletoe (Viscum
album L. grown on ash trees) (Koehler, 1992) and it is the
preparation with the highest lectin content (Scheer, 1996). We
herein, report the results of a phase II study to evaluate its efficacy
and safety in the treatment of patients with advanced HCC.
PATIENTS AND METHODS
Eligibility criteria
The eligibility criteria included: (1) pathology proven primary
HCC or a-fetoprotein 4400ng/ml with a hepatic tumor highly
suggestive of HCC by imaging studies; (2) unresectable tumor and
patient was not a candidate for either transcatheter arterial
chemoembolization (TACE) or percutaneous ethanol injection
(PEI); (3) bi-dimensional measurable disease; (4) no previous
systemic chemotherapy; (5) age between 16 years and 75 years; (6)
performance status 0–3 WHO, 7) within normal renal, cardiac and
hematological profile.
Treatment protocol
Prior to entry into the study, all patients provided a complete
history and physical examination, including performance status,
concurrent nonmalignant diseases and therapy. Laboratory studies
included a complete blood cell counts, differential count,
biochemical liver and renal function tests, electrolyte, chest x-
rays, a-fetoprotein, triphasic liver computed scan (CT) and Child
class evaluation were performed before treatment. The mistletoe
preparation for the study is an aqueous injectable solution. It
contains one milliliter of viscum fraxini in dilution stage–2 (15mg
extract of 20mg mistletoe herb from ash tree, diluted in di-
natrium-mono-hydrogen phosphate, ascorbic acid and water)
which is equivalent to 10000ng/ml injection ampoules. 2 ampoules
of viscum fraxini–2 were administered subcutaneously once
weekly. Patients were seen on a weekly basis during treatment
for history taking and physical examination. A complete blood
count was determined every week. Renal and liver functions and a-
fetoprotein levels were examined every 4 weeks. The tumor was
assessed by CT every 8 weeks.
Definition of response
Determination of the tumor response followed standard response
criteria established by the World Health Organization (WHO)
(Miller et al, 1981). Complete response (CR) was defined as the
complete disappearance of all known lesions on radiological
grounds for at least 4 weeks. Partial response (PR) was defined as a
decrease of 50% or more in the product of two perpendicular
diameters of the largest tumor nodule for at least 4 weeks without
the appearance of new lesions or progression of lesions. Static
disease (SD) was defined as a o50% decrease, or not more than a
25% increase, in the product of two perpendicular diameters of the
largest tumor nodule. Progressive disease (PD) was defined as
425% increase in the product of two perpendicular diameters of
the largest tumor nodule or one of the measurable lesions, or the
appearance of new lesions. Patients who did not survive to
reassessment by radiological methods were considered to have
undetermined response (UR).
Toxicity
Evaluation of toxicity, classified according to the criteria of the
WHO (World Health Organization, 1979) included physical
examination prior to every injection, complete blood cell counts
and serum assessment of renal and hepatic functions. Each patient
after having at least one dose of protocol therapy was evaluable for
toxicity.
Statistical analysis
Descriptive statistics are reported as percentages and medians. The
overall survival time was calculated from the start of therapy to the
date of death or the last visit of the patient. The time to disease
progression was defined from the start of therapy to the date of
disease progression. Survival curves were constructed using the
Kaplan-Meier productlimit method (Kaplan and Meier, 1959).
Study approval
The study was approved by the local ethics committee and all
patients signed informed consent before entering the study.
RESULTS
Patient characteristics
Base line patient characteristics and clinical features are summar-
ized in Table 1. Twenty-three patients were entered into the trial.
They were 20 males and 3 females, aged 39–75 years with a median
of 54 years. Their WHO performance status was 1 in 10 patients
(43.5%), 2 in 7 patients (30.4%) and 3 in 6 patients (26.1%). HbsAg
Table 1 Patients Characteristics
Characteristic No. of patients %
Male: female (total) 20:3 (23)
Median age in years (range) 54 (39–75)
Performance status
1 10 43.5
2 7 30.4
3 6 26.1
Hepatitis
HbsAg (+) 13 56.5
Anti HCV (+) 8 34.8
Both (+) 2 8.7
Child’s classification
A 9 39.1
B 6 26.1
C 8 34.8
Okuda stage:
I 4 17.4
II 12 52.2
III 7 30.4
Diagnosis:
Cytology 14 60.9
a-fetoprotein and imaging 9 39.1
Tumor status
Bilateral lobe affection 8 34.8
Unilateral lobe affection 15 65.2
Distant metastasis 4 17.4
Main Portal vein Thrombosis 2 8.7
Ascites 4 17.4
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land anti HCV were positive in 13 patients (56.5%) and 8 patients
(34.8%), respectively, while 2 patients (8.7%) were positive for
both. All patients were chemotherapy naı ¨ve. The median duration
of treatment on viscum fraxini-2 is 17 weeks (range 3–152 weeks).
Okuda stage I was found in 4 patients (17.4%), stage II in 12
patients (52.2%) and stage III in 7 patients (30.4%). The diagnosis
of HCC was based on fine-needle aspiration cytology of liver
tumors in 14 patients (60.9%). The remaining 9 patients (39.1%)
were diagnosed by marked elevation of a-fetoprotein level and
imaging studies indicating advanced HCC. All of the patients had
far-advanced HCC at the time of diagnosis. Bilateral lobar affection
of the liver was present in 8 patients (34.8%). Extensive one lobe
affection was present in 15 patients (65.2%). Distant metastasis
were present in 4 patients (17.4%) (2 bone metastasis and 2 lymph
node metastasis). Main portal vein thrombosis was detected in two
patients (8.7%) while ascites was present in 4 patients (17.4%).
Response
According to conventional radiological response criteria, 3
patients (13.1%) achieved complete response. The first patient
achieved CR after 4 months from starting the treatment and
remained disease free for 4 months. The second and the third
patients achieved CR after 6 months and they are still living disease
free for more than 29 and 38 months, respectively (CT scan of the
third patients before treatment and after disappearance of the
tumor is shown in Figure 1). 2 patients (8.7%) achieved partial 9
response. Progressive disease has been shown in 9 patients
(39.1%). 9 patients (39.1%) did not have evaluation of response
due to early death and they were classified as UR.
Survival
At the time of analysis, 3 (13.1%) patients remained alive including
two patients with CR and one patient with slowly progressive
disease. The median overall survival time for all patients was 5
months (range 2–38 months), for those who achieved a CR was 29
months (range 12–38 months) and, for those who achieved a PR
was 6.5 months (range 6–7 months). The median progression free
survival for all patients was 2 months (range 1–38 months), for
those who achieved a CR, it was 29 months (range 8–38 months)
and for those who achieved a partial response, it was 5 months
(range 4–6 months). The Kaplan- Meier actuarial overall survival
and PFS curves for all patients are shown in Figure 2.
Toxicity
All patients were evaluated for toxicity. Drug related fever
developed in 8 patients (34.8%). Erythma at injection site
developed in 3 patients (13.1%). 4 patients (17.4%) suffered pain
at site of injection. 3 patients had to reduce the dose to one
ampoule on the subsequent treatment courses. Anti-inflammatory
and analgesics were used in only one patient due to severe pain
and erythma at injection site. There were no drug related
discontinuation or toxic deaths.
DISCUSSION
Hepatocellular carcinoma is one of the most common cancers
worldwide (Okuda, 1980). Resection is perhaps the only mean-
ingful chance of cure. Although early diagnosis is becoming more
frequent, particularly in those populations subjected to screening
programs, resection rates for patients with HCC remain low (Lee
Figure 1 A case of hepatocellular carcinoma with multiple focal lesions
before treatment (A) with regression of the tumor (B) and disappearance
of the tumor (C) after 6 months of viscum fraxini-2 therapy.
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let al, 1982 and Okuda et al, 1985). Therefore, the vast majority of
patients with HCC are not candidates for curative surgery or other
local therapy and systemic chemotherapy may be the only option
for their treatment.
The antitumor activities of a number of chemotherapeutic
agents have been evaluated in HCC patients, but most yielded poor
results and probably are associated with severe side effects.
Doxorubicin remains the most active drug against HCC, with a
single agent tumor response rate of about 10–20%. However, its
toxicity outweighs its benefit (Lai et al, 1988; Lai et al, 1990).
Chemotherapeutic agents other than doxorubicin have demon-
strated even less activity and progress in treating HCC patients
with chemotherapy has been disappointing. New chemotherapeu-
tic drugs, such as paclitaxel, raltrexed, irinotecan, and nolatrexed,
have not demonstrated encouraging results. These new drugs
exhibit some antitumor activity, but response rates rarely exceed
10% (Rougier et al, 1997; Chao et al, 1998; O’Reilly et al, 1998;
Stuart et al, 1999). The possible explanations for the refractioness
of HCC to chemotherapy include tumor heterogeneity (Dexter and
Leith, 1986), inadequate dosage of anticancer agents (Lai et al,
1990) and the inducible overexpression of the multidrug resistance
gene (Huang et al, 1992). Therefore, all patients with advanced
HCC should be considered for joining well– designed phase II
trials with novel antitumor agents or regimens when patients can
tolerate treatment.
Viscum fraxini is an aqueous extract of mistletoe. Controversy
exists as to how the plant extracts exert their postulated dual
activity of cytotoxicity towards tumor cells and stimulation of
immune cells (Janssen et al, 1993).
Immunostimulatory effects of mistletoe extract have been
assigned to a low molecular weight oligosaccharide compound
(Hamprecht et al, 1987; Mueller et al, 1989). Moreover, the
stimulatory effect on natural killer (NK) cell activity appears to
result from enhanced production of interferon (INF-g) and tumor
necrosis factor-a (TNF-a) by T cells and macrophages respectively
(Mueller and Anderer, 1990). On the other hand, there is some
evidence that lectin components are important effector molecules
in mistletoe preparations (Luther and Becker, 1987). The lectin
components increase the total number and the activities of
neutrophils, NK cells and large granular lymphocytes as well as
they activate simultaneously monocyte-macrophage and helper
cell subpopulations. This was associated with higher levels of
cytokines such as interleukins IL-1, IL-6, granulocyte macrophage
colony stimulating factor (GM-CSF) and TNF-a (Hajto et al, 1990,
Schultze et al, 1991; Beuth et al, 1993).The described immunolo-
gical effects of mistletoe polysaccharides are supplemented by
membrane lipids. As shown by Hartmann et al (1995) isolated
vesicles of genuine membrane systems were the most potent
stimulating factor for T-cell proliferation of mistletoe extracts
(Hartmann et al, 1995).
Apart from the immunostimulatory effect of mistletoe extract
and lectins, it has been reported that they have a direct cytotoxic
effect (Ribereau–Gayon et al, 1986; Urech et al, 1996). Lectins are
considered essential components of mistletoe aqueous extract
responsible for apoptosis (Janssen et al, 1993). Viscotoxins which
are a group of cytotoxic polypeptides belonging to the class of
thionins (Schrader-Fischer and Apel, 1993) can enhance the
permeability of cell membrane (Lankish and Vogt, 1978). So,
mistletoe extracts are able to induce both ways of biological cell
death; apoptosis and lysis. Moreover, these initial effects subse-
quently induce immune stimulating reactions.
Taken together, complete mistletoe extract containing mem-
brane lipids like viscum fraxini affects both arms of immune
system, the T-cell and the B-cell parts, initially inducing
proliferation and activation of immune competent cells as well
as expression of cytokines, supporting antitumoral effects.
In the light of these observations, the present study aimed to
improve efficacy of systemic chemotherapy. HCC patients with
inoperable disease or exrtahepatic disease who were not suitable
for regional intra-arterial treatment were enrolled in this study.
The treatment resulted in an overall response rate of 21.74% (5/23)
with a good impact on survival. While most of Phase II trials of
treatment of HCC confirmed that there is no effective drug for
HCC and all single systemic anticancer agents produced a response
rate of less than 10% (Yoshida et al, 1988; Lin et al, 1993; Okada
et al, 1993; Wierzbicki et al, 1994; Falkson and Burger, 1995),
Viscum Fraxini-2 in our study showed encouraging results and
might represent a good opportunity for treating patients with
advanced HCC.
In conclusion, Viscum Fraxini-2 is active in HCC with anti-
tumor activity and low toxicity profile. Further studies in
combination with other active agents are clearly warranted.
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